Fig. 3From: Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trialThe cancer targeting accuracy will be quantified via paired control by comparing the targeting error that would have been present without KIM (above) to the targeting error with KIM corrections (below)Back to article page